We just finished talking to over 200 hundred HCPs about pharma marketing and salespeople to measure any differences since before the pandemic. Attitudes are indeed changing, but one need remains clear: access to data obtained during clinical and ongoing trials.
The old model of looking at performance in the first six months of product launch isn’t relevant. Today, colossal budget product launches are not returning the same ROI as before. Product launches are going to need to be micro-targeted to specific audiences.
Biotech start-ups face challenges in raising money and cutting through the “noise” of other prominent pharma marketers, but their website can provide a wealth of insights into what visitors want to know.
Omnichannel is the latest buzzword-making rounds within pharma, but omnichannel has no relevance if your message is too promotional or is irrelevant to your audience. The channel IS essential but not as important as your message.
A Mediabistro survey showed that social networks influence more than 40% of people’s health choices. Tik-Tok, Instagram, and other social media channels may soon be overwhelmed with pharma companies’ content, but is it a good idea?
Yes, there will be changes in healthcare in the coming years but put away the thoughts that telehealth and wearable devices will revolutionize healthcare. More and more patients demand a level of service they want with the increased costs of health insurance premiums. Here are things I believe are more realistic.
LEAD-IN- Recent data confirms that health care professionals are using the Internet more and spending less time with drug company reps. How much should you spend on an HCP portal, and how do you measure its success?
SUMMARY: When it comes to reaching health care professionals, there is only one choice as far as I am concerned, and that’s Medscape. Working with them has always been a pleasure, and we can always “list match” targeted physicians.